Patiño FJL, Hidalgo MSM

Language: Spanish
References: 34
Page: 337-349
PDF size: 371.81 Kb.

ABSTRACT

Introduction: sepsis is a deadly and common disease. It's one of the few medical conditions that attack's the same and with great ferocity both populations with scarce resources as much as populations with high incomes. In patients with an inflammatory process, the rise in the concentration of proinflammatory cytokines could lead to a release of platelets, which leads afterwards to a diminish in the platelet count and inversely to change in the platelet morphology (rising the size to variable values of mean platelet volume (MPV). It is important to determine early biomarkers that helps identify with an easy and economic way to facilitate detection and help predict mortality. Objective: determine the mean platelet volume as a biomarker of inflammatory response as an early indicator of mortality in patients infected with COVID-19. Material and methods: a cohort, observational, prospective, comparative and longitudinal study was carried out. Results: a MPV ≥ 7.4 fL did increase mortality 3.1 times between the selected patients (IC of 95% 1.3 - 7.5, p = 0.016). Conclusion: COVID-19 behaves like an infection that can involve multiple organs or systems of the host. Many studies suggest that hematologic profiles change during the course of the SARS-CoV-2. The production of platelets rises as it decreases the platelet count. Nevertheless, more studies are needed that allow us to clarify this mechanisms.

REFERENCES

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.

2. Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD. Estudio epidemiológico de la sepsis en unidades de terapia intensiva mexicanas. Cir Cir. 2009;77(4):301-308.

3. Carrillo Esper R, Peña Pérez CA, Sosa García JO. Sepsis. De las bases moleculares a la campaña para incrementar la supervivencia. México: Intersistemas; 2015. Disponible en: https://www.anmm.org.mx/publicaciones/CAnivANM150/L31_ANM_SEPSIS.pdf

4. Sánchez CA, Navarro AJL, Delgado ALY, Torres AO, Franco GJ, Aguirre SJ et al. Utilidad del volumen plaquetario medio para descartar sepsis. Med Crit. 2016;30(2):87-94.

5. Vélez JL, Vélez P, Jara A, Bucheli R. ¿Es el volumen medio plaquetario un predictor de mortalidad en sepsis? Rev Fac Cien Med (Quito). 2017;42(1):83-88.

6. Vélez JL. ¿El volumen medio plaquetario es un predictor de mortalidad en pacientes sépticos?: Revisión de la literatura. Rev Med Hered. 2018;29(2):116-120.

7. Vardon-Bounes F, Gratacap MP, Groyer S, Ruiz S, Georges B, Seguin T, et al. Kinetics of mean platelet volume predicts mortality in patients with septic shock. PLoS One. 2019;14(10):e0223553.

8. Wu CC, Lan HM, Han ST, Chaou CH, Yeh CF, Liu SH, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. Ann Intensive Care. 2017;7(1):91.

9. Dewitte A, Lepreux S, Villeneuve J, Rigothier C, Combe C, Ouattara A, et al. Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critically [corrected] ill patients? Ann Intensive Care. 2017;7(1):115.

10. Schmitt FCF, Manolov V, Morgenstern J, Fleming T, Heitmeier S, Uhle F, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care. 2019;9(1):19.

11. Oh GH, Chung SP, Park YS, Hong JH, Lee HS, Chung HS, et al. Mean platelet volume to platelet count ratio as a promising predictor of early mortality in severe sepsis. Shock. 2017;47(3):323-330.

12. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165-228.

13. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581-614.

14. van Engelen TSR, Wiersinga WJ, Scicluna BP, van der Poll T. Biomarkers in sepsis. Crit Care Clin. 2018;34(1):139-152.

15. Grupo de Trabajo Mexicano COVID-/COMMEC. Guía COVID-19 para la atención del paciente crítico con infección por SARS-CoV-2 Colegio Mexicano de Medicina Crítica. Med Crit. 2020;34(1):7-42.

16. Gutiérrez-Romero A, Gutiérrez-Grobe Y, Carrillo-Esper R. Volumen plaquetario medio: el tamaño sí importa. Med Int Mex. 2013;29(3):307-310.

17. Korniluk A, Koper-Lenkiewicz OM, Kami?ska J, Kemona H, Dymicka-Piekarska V. Mean platelet volume (MPV): new perspectives for an old marker in the course and prognosis of inflammatory conditions. Mediators Inflamm. 2019;2019:9213074.

18. Keller DM. Platelet size predicts mortality in patients with sepsis. Medscape [Internet]. 2012. Available in: https://www.medscape.com/viewarticle/767116?src=trendmd_pilot

19. Kim JH, Lee Y, Cho YS, Sohn YJ, Hyun JH, Ahn SM, et al. A modified simple scoring system using the red blood cell distribution width, delta neutrophil index, and mean platelet volume-to-platelet count to predict 28-day mortality in patients with sepsis. J Intensive Care Med. 2021;36(8):873-878.

20. Kim CH, Kim SJ, Lee MJ, Kwon YE, Kim YL, Park KS, et al. An increase in mean platelet volume from baseline is associated with mortality in patients with severe sepsis or septic shock. PLoS One. 2015;10(3):e0119437.

21. Manrique AF, Méndez FY, Herrera-Amaya G, Rodríguez J, Manrique-Abril R. Uso de procalcitonina como diagnóstico de sepsis o shock séptico: revisión sistemática y metaanálisis. Infect. 2019;23(2):133-142.

22. Fung AWS, Beriault D, Diamandis EP, Burnham CD, Dorman T, Downing M, et al. The role of procalcitonin in diagnosis of sepsis and antibiotic stewardship: opportunities and challenges. Clin Chem. 2017;63(9):1436-1441.

23. Anurag A, Jha PK, Kumar A. Differential white blood cell count in the COVID-19: A cross-sectional study of 148 patients. Diabetes Metab Syndr. 2020;14(6):2099-2102.

24. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834-847.

25. Kitazawa T, Yoshino Y, Tatsuno K, Ota Y, Yotsuyanagi H. Changes in the mean platelet volume levels after bloodstream infection have prognostic value. Intern Med. 2013;52(13):1487-1493.

26. Hvas AM. Platelet function in thrombosis and hemostasis. Semin Thromb Hemost. 2016;42(3):183-184.

27. Ribeiro LS, Migliari Branco L, Franklin BS. Regulation of innate immune responses by platelets. Front Immunol. 2019;10:1320.

28. Ekiz F, Yüksel O, Kocak E, Yilmaz B, Altinbas A, Coban S, et al. Mean platelet volume as a fibrosis marker in patients with chronic hepatitis B. J Clin Lab Anal. 2011;25(3):162-165.

29. Ozder A. A novel indicator predicts 2019 novel coronavirus infection in subjects with diabetes. Diabetes Res Clin Pract. 2020;166:108294.

30. Ozcelik N, Ozyurt S, Yilmaz Kara B, Gumus A, Sahin U. The value of the platelet count and platelet indices in differentiation of COVID-19 and influenza pneumonia. J Med Virol. 2021;93(4):2221-2226.

31. Guclu E, Kocayigit H, Okan HD, Erkorkmaz U, Yürümez Y, Yaylaci S, et al. Effect of COVID-19 on platelet count and its indices. Rev Assoc Med Bras (1992). 2020;66(8):1122-1127.

32. Koupenova M, Kehrel BE, Corkrey HA, Freedman JE. Thrombosis and platelets: an update. Eur Heart J. 2017;38(11):785-791.

33. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost. 2010;8(1):148-156.

34. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;99(6):1205-1208.